Your search matched 9 results
While federal drug pricing reform in the Build Back Better Act (BBBA) is stalled at the Senate, states are taking the issue into their own hands.
In November 2022, Sen.
On July 1st, The Centers for Medicare & Medicaid Services, through its Center for Medicare & Medicaid Innovation (CMMI), announced its newest voluntary oncology payment model, Enhancing Oncology Model (EOM).
The Food and Drug Administration (FDA) approved Alzheimer’s disease (AD) drug lecanemab through its accelerated approval program.
With a global pandemic, rising inflation, and continued political pressures, drug pricing will undoubtedly remain a big focus in 2022.
What the CMS National Coverage Decision Means for the Life Science Industry
In July, the Institute for Clinical and Economic Review (ICER) published its final evidence report for bluebird bio’s Zynteglo (betibeglogene autotemcel or “beti-cel”) for the treatment of beta thalassemia, a rare, debilitating blood disorder.
The Institute for Clinical and Economic Review (ICER) recently published the white paper “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability.”
The Biden administration cited health equity as one of its top 5 health priorities in a Health Affairs blog.